Johnson & Johnson’s stock price surged as the company revised its estimate of tariff costs for 2025, slashing it to $200 million. This move is seen as a positive signal for investors.
According to CEO Joaquin Duato, Johnson & Johnson expects “elevated growth” in the second half of the year, indicating an improvement in its financial outlook. The revised estimate and outlook have contributed to the company’s stock price increase.
Source: https://www.marketwatch.com/story/johnson-johnsons-stock-rallies-after-earnings-beat-and-outlook-raised-amid-strength-in-heart-and-cancer-treatments-5d66f50b